TCR2 Therapeutics Inc. TCRR
1.48 0.00 (+0.00%)
At closeMay 31, 2023, 4:00 PM EDT
1.48 Day range 1.48
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) 6.43 +334.5% upside
Now 1.48
- Target (low)
- 1.72
- Target (mean)
- 6.43
- Target (high)
- 20.00
Ratings (-1m) 8 1 buy · 7 hold · 0 sell
- Strong buy0
- Buy1
- Hold7
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 8
- 2 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.64 | -0.64 – -0.64 | -0.82 | +22.0% | 0 | 0.0% | 1 |
| Next quarter | -0.65 | -0.65 – -0.65 | -0.79 | +17.7% | 0 | 0.0% | 1 |
| Current year | -2.78 | -2.78 – -2.78 | -3.93 | +29.3% | 0 | 0.0% | 1 |
| Next year | -2.46 | -2.46 – -2.46 | -2.78 | +11.5% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 24, 2023 | Mizuho | Downgrade | Buy | Neutral |
| Mar 23, 2023 | EF Hutton | Reiterated | — | Hold |
| Mar 9, 2023 | Jefferies | Downgrade | Buy | Underperform |
| Mar 8, 2023 | Truist Securities | Downgrade | Buy | Hold |
| Mar 7, 2023 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jan 6, 2023 | Piper Sandler | Maintained | — | Overweight |
| Jan 5, 2023 | EF Hutton | Initiated | — | Hold |
| Nov 21, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 8, 2022 | SVB Leerink | Maintained | — | Market Perform |
| May 19, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Mar 23, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Jan 19, 2022 | Goldman Sachs | Downgrade | Buy | Neutral |
| Jan 13, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 10, 2021 | SVB Leerink | Maintained | — | Market Perform |
| Oct 21, 2021 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Sep 20, 2021 | Truist Securities | Maintained | — | Buy |
| Sep 20, 2021 | Wedbush | Downgrade | Outperform | Neutral |
| Sep 20, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 6, 2021 | SVB Leerink | Maintained | — | Outperform |
| Jun 24, 2021 | Goldman Sachs | Initiated | — | Buy |
| Mar 11, 2021 | SVB Leerink | Maintained | — | Outperform |
| Dec 14, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 30, 2020 | Roth Capital | Maintained | — | Buy |
| Aug 21, 2020 | Mizuho | Initiated | — | Buy |
| Aug 13, 2020 | Truist Securities | Initiated | — | Buy |
| Aug 13, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 12, 2020 | SVB Leerink | Maintained | — | Outperform |
| Aug 12, 2020 | Piper Sandler | Initiated | — | Overweight |
| Jul 27, 2020 | Roth Capital | Upgrade | Neutral | Buy |
| Jul 27, 2020 | HC Wainwright & Co. | Maintained | — | Buy |